The need for an integrated approach for chronic disease research and care in Africa

A. L. Barr1,2, E. H. Young1,2, L. Smeeth3, R. Newton4, J. Seeley4,5, K. Ripullone1,2, T. R. Hirip1,2, J. R. M. Thornton1,2, M. J. Nyirenda3,8, S. Kapiga3,7, C. A. Adebamowo8,9, A. G. Amoah10, N. Wareham11, C. N. Rotimi12, N. S. Levitt13, K. Ramaiya14, B. J. Hennig15,16, J. C. Mbanya17, S. Tollman18,19, A. A. Motala20, P. Kaleebu4, M. S. Sandhu1,2* and On behalf of the African Partnership of Chronic Disease Research

1 Department of Medicine, University of Cambridge, Cambridge, UK
2 Wellcome Trust Sanger Institute, Genome Campus, Hinxton, UK
3 Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
4 Medical Research Council/Uganda Virus Research Institute (MRC/UVRI), Uganda Research Unit on AIDS, Entebbe, Uganda
5 Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK
6 Malawi Epidemiology and Intervention Research Unit, Lilongwe, Malawi
7 Mwanza Intervention Trials Unit, National Institute for Medical Research, Mwanza, Tanzania
8 Department of Epidemiology and Public Health, Greenbaum Comprehensive Cancer Center and Institute of Human Virology, University of Maryland School of Medicine, Baltimore MD 21201 USA
9 Institute of Human Virology, Nigeria
10 Department of Medicine, University of Ghana Medical School, Korlebu, Ghana
11 MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
12 Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, USA
13 Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa
14 Shree Hindu Mandal Hospital, Dar es Salaam, Tanzania
15 MRC Unit, The Gambia, Fajara, The Gambia
16 MRC International Nutrition Group, London School of Hygiene & Tropical Medicine, London, UK
17 Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
18 MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
19 INDEPTH Network, Accra, Ghana
20 Department of Diabetes and Endocrinology, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

Global Health, Epidemiology and Genomics (2016), 1, e19, page 1 of 6. doi:10.1017/gheg.2016.16

With the changing distribution of infectious diseases, and an increase in the burden of non-communicable diseases, low- and middle-income countries, including those in Africa, will need to expand their health care capacities to effectively respond to these epidemiological transitions. The interrelated risk factors for chronic infectious and non-communicable diseases and the need for long-term disease management, argue for combined strategies to understand their underlying causes and to design strategies for effective prevention and long-term care. Through multidisciplinary research and implementation partnerships, we advocate an integrated approach for research and healthcare for chronic diseases in Africa.

Received 18 February 2016; Revised 9 August 2016; Accepted 11 September 2016

Key words: Africa, chronic disease, health systems, implementation, integration, intervention, low and middle income countries, non-communicable disease, partnerships, research, surveillance, technology, infectious disease.

© The Author(s) 2016. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited

https://doi.org/10.1017/gheg.2016.16 Published online by Cambridge University Press
Burden of non-communicable diseases (NCDs) in Africa

Chronic NCDs such as diabetes, cardiovascular diseases (CVD), and cancers are emerging as leading causes of mortality and morbidity in Africa. In this region, with a population of around 1.1 billion, there were an estimated 28 million adults living with diabetes in 2015 [1, 2]. It is anticipated that in sub-Saharan Africa (SSA) alone, the number of people living with the disease will rise to 34.2 million by 2040 [2]. Similarly, in 2015, a projected 1.6 million deaths were attributable to CVD in Africa [3]. This figure is expected to rise by another 1 million by 2030 [3]. Cancer-related deaths are also anticipated to double to 1.2 million by 2030 [3]. Close to one-third of NCD-related deaths in low- and middle-income countries (LMICs) are premature and occur before the age of 60 [4]. Thus, NCDs already present a major health burden for the African continent and are expected to be the most common cause of death, exceeding the number of deaths from communicable, maternal, perinatal, and nutritional diseases combined, by 2030 [5].

Risk factors for NCDs in Africa

Because of the diverse social, environmental, and biological settings within Africa, the distributions of known and other potentially novel risk factors, and their determinants, are likely to differ from those of European populations or those of African descent living outside Africa [6]. The higher incidence of certain cancers, such as liver, cervical and oesophageal, in Africa compared with high-income countries (HICs) may reflect underlying differences in their risk factors in these regions [7]. Population growth and the concomitant rise in life expectancy are likely to only partly explain the increase in NCDs. Many of the known risk factors for NCDs in HICs are the same for LMICs, including smoking, alcohol, diet, obesity, raised cholesterol and blood pressure [8, 9]. However, the distribution and relative contribution of these risk factors to the burden of NCDs in Africa are unclear. We also have only a limited understanding of the social, environmental and biological drivers of these risk factors within African populations. Rapid urbanisation and globalisation, and the associated trends towards unhealthy lifestyles, contribute to the burden of NCDs [10]. Small increases in urbanisation are associated with lower levels of physical activity and higher body mass index [11–13]. Globalisation has increased the availability of cheap, nutrient-poor, and energy-dense foods, which are likely to increase the risk of obesity and associated cardiometabolic risk factors [14]. Notably, the high burden of NCDs in rural areas, as well as urban centres, suggest there may be additional contributing or distinct factors [15].

Impact of maternal and childhood health on NCDs in Africa

Maternal and neonatal health and risk of NCDs are interrelated. The prevalence of overweight and obesity in adult women in Africa has been rising; between 1980 and 2013, the burden of overweight and obesity in females increased by an average of 10% [16]. Maternal obesity increases the risk of developing gestational diabetes [17], and is associated with poor maternal and neonatal outcomes [18–20]. Women who develop diabetes and hypertension during pregnancy have an increased risk of type 2 diabetes (T2D), CVD, and metabolic syndromes [19, 21–23]. Children of obese or diabetic mothers also have a higher risk of metabolic disease in later life [24]. By contrast, under-nutrition in utero or in early life may also result in an increased risk of T2D and CVD in adulthood [25–28]. Adaptive responses to exposures in utero are thought to prepare the foetus for the postnatal environment [25]. Rapid changes in the nutritional environments, as seen in many LMICs, could lead to an increase in NCDs [25–27]. These maternal and developmental risk factors may have a social, environmental, or biological basis, and are intergenerational – highlighting the complexity of the epidemiological transitions across the African continent, and in other LMICs [28, 29, 30].

Changing burden of infectious disease in Africa

Substantial progress has been made in reducing the burden of many types of infectious diseases, including those in early childhood. However, tuberculosis (TB), malaria, and HIV, as well as hepatitis B and C, remain endemic across the region. Africa has the highest burden of HIV in the world, with approximately 26 million prevalent cases and 1.3 million new infections recorded in 2014 [31]. TB and HIV co-infection is a growing issue in many LMICs [32]; as such, it is the most common cause of death for people with AIDS [33]. Anti-retroviral therapy (ART) coverage in Africa has rapidly increased over the past decade; 51% of known cases in SSA received treatment in 2012 [34]. Expanding use of ART has led to a notable decline in HIV-associated morbidity and mortality in Africa; HIV is rapidly becoming a chronic disease, requiring long-term treatment and management. This and the emergence of drug resistant strains of HIV, malaria, TB, and other pathogens pose a major challenge for the continent’s infectious disease control and management programmes, which may also have implications for the burden of NCDs [35, 36].

Interrelationship between non-communicable and infectious disease in Africa

The interrelated risk factors for infectious and non-communicable diseases are likely to have an important impact on the spectrum and distribution of chronic diseases in Africa, and other LMICs undergoing similar epidemiological transitions. The immune and metabolic systems are closely integrated, with each system’s response dependent on the other for normal function [37]. Evolving from a common antecedent organ, they have shared and overlapping signalling pathways [37].
Chronic inflammation has been unequivocally linked to obesity, insulin resistance, T2D, and an increased risk of malignancy \[37, 38\]. Likewise, several infectious diseases and their treatments are associated with an increased risk of NCDs \[39\]. HIV and ART may increase the burden of cardiometabolic risk factors, including lipid and glucose abnormalities \[40–43\]. Hepatitis B and C infection may also increase the risk of developing T2D \[44–46\], as well as chronic liver disease and hepatocellular cancers, in addition to other oncogenic pathogens \[47\]. Similarly, insulin resistance and T2D may influence clinical outcomes in patients with hepatitis-associated liver disease and cancer \[48\]. Endemic infectious diseases may have also had an impact on selective adaptation and risk of NCDs – for example, renal function and African trypanosomiasis \[49\]. Thus, the body’s own immune response, endemic and chronic infections, and their treatments, may play an important role in the development and progression of NCDs in Africa, although the underlying mechanisms are not well understood.

The need for surveillance and prospective studies in Africa

Understanding the aetiology and determinants of NCDs in Africa is a fundamental step in developing strategies for disease prevention, management and control. Crucially, the impact of population and individual risk factors on disease susceptibility is largely unknown. Usually, chronic disease risk prediction models applied to African populations are based on regional comparisons of national indices, cross-sectional or case-control assessments, and the extrapolation of risk prediction algorithms developed in populations in Europe and elsewhere \[50–52\]. Furthermore, those studies conducted in African populations often use varying methods and definitions, or only assess a small subset of potential risk factors, limiting comparative analysis \[53–55\].

Whilst research institutions in Africa have clearly developed research frameworks for assessing the epidemiological and clinical burden of chronic disease across the region, there is a need to integrate and scale up such efforts \[6, 40, 51, 56\]. The INDEPTH Network of health and demographic surveillance systems is an example of a pragmatic model for examining disease burden across different settings \[57–59\]. Utilizing such established surveillance systems and analogous research initiatives to implement high quality and comparable large-scale population-based studies across the spectrum of chronic diseases and their risk factors will be crucial to understanding the aetiology and burden of chronic diseases in Africa. Likewise, implementation of standardised tools for the measurement of NCD risk factors in LMICs, such as those developed by the WHO, will enable comparability \[60\]. Importantly, establishing prospective studies in these settings will provide an invaluable framework to evaluate the utility of existing generic cut-off points or develop specific risk prediction algorithms for African populations, and provide the foundations for future aetiological and healthcare interventions.

The need for research into the implementation of integrated health services and the management of chronic diseases in Africa

Aligning epidemiological and implementation research will provide the most effective strategy to identify pragmatic solutions for delivering chronic disease health care. The emerging double burden of chronic infectious and non-communicable disease imposes a substantial strain on limited healthcare resources and has implications for health policy and planning. In many African countries, where health systems are fragile, under-resourced or targeted primarily to infectious diseases, the capacity to effectively deal with the burden of chronic NCDs and accompanying comorbidities is severely limited \[61, 62\]. These health system challenges will only become more apparent as the prevalence of NCDs increases.

Chronic infectious and non-communicable disease programmes in Africa have traditionally been distinct at all levels of healthcare provision. However, emerging evidence suggests that an integrated approach to the broad spectrum of chronic diseases may provide the most cost-effective mechanism for disease treatment and control due to the related underlying pathogenesis and strategies for management \[63, 64\]. Integrating NCD management with existing HIV/AIDS/TB, malaria, and maternal and child health programmes would utilise existing infrastructure, and allow for more rapid implementation of NCD health care \[65\]. Ideally these services would be placed within a strengthened and well-resourced primary health care system that can provide pro-active, patient-centric and long-term community-based care \[66\]. However, a more complete understanding of the broad range of risk factors, and their interrelation, will be critical in designing such integrated health care systems – and provide mechanisms for broader preventative strategies. In these contexts, it is vital to conduct public health implementation research to fully explore the most effective and economic strategies to deliver accessible and integrated health care for chronic diseases \[67–70\]. Universal implementation of existing low cost interventions for the diagnosis and management of NCDs and infectious diseases would be a pivotal first phase \[66\].

Likewise, it will be important to identify the most effective strategies for chronic disease management for the African context; reliable information on the efficacy of drug treatments for NCDs and infectious diseases, and their adverse reactions in African populations is limited \[71, 72\]. Harnessing and integrating existing health and pharmacovigilance systems could also facilitate drug efficacy trials and monitoring. Evaluation of current and novel chronic disease diagnostics, treatment and management strategies, including point of care testing and low-cost technology-based
interventions within resource-limited settings, will be vital to implementing efficient mechanisms for integrated chronic disease research and care across the region, and in translating research findings into health care policy and services [73, 74].

An integrated approach to chronic disease research and care in Africa

NCDs and infectious diseases should not be viewed as distinctive fields within global health research [75]. There is a critical need to combine research efforts across both acute and chronic infectious diseases and NCDs to better understand their interrelation and to develop more effective health systems to provide long-term management and care. Research and implementation partnerships will need to adopt innovative multidisciplinary research agendas that both strengthen and integrate existing infrastructure and advance implementation science. Combined, such structures could allow the formation of large-scale population health resources that would enable comprehensive studies into the diagnosis, prevention and management of chronic diseases, and their complex interactions, over diverse settings [76].

Acknowledgements

This work was funded by the African Partnership for Chronic Disease Research strategic award from the UK Medical Research Council under the MRC/DFID Concordat agreement (grant number MR/K013491/1). We also acknowledge the National Institute for Health Research Cambridge Biomedical Research Centre.

Declaration of Interest

All authors have no conflicts of interest to declare.

References

1. United Nations. Population and Vital Statistics Report. 2015.
2. IDF. IDF Diabetes Atlas, 7th edn. Brussels: International Diabetes Federation, 2015.
3. WHO. Global health estimates summary tables: projection of deaths by cause, age and sex, by World Bank income groups: World Health Organization; 2013 [8th of June 2015]. (http://www.who.int/healthinfo/global_burden_disease/projections/en/).
4. WHO. Global Status Report on Non-communicable Diseases 2010. Geneva: World Health Organization, 2011.
5. WHO. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization, 2008.
6. Gurdasani D, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature 2014; 517: 327–332.
7. Ferlay J, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010; 127: 2893–2917.
8. Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
9. Murphy GA, et al. Sociodemographic distribution of non-communicable disease risk factors in rural Uganda: a cross-sectional study. International Journal of Epidemiology 2013; 42: 1740–1753.
10. BeLue R, et al. An overview of cardiovascular risk factor burden in sub-Saharan African countries: a socio-cultural perspective. Globalization and Health 2009; 5: 10.
11. Rija J, et al. Urbanicity and lifestyle risk factors for cardiometabolic diseases in rural Uganda: a cross-sectional study. PLoS Medicine 2014; 11: e1001683.
12. Assah FK, et al. Urbanization, physical activity, and metabolic health in sub-Saharan Africa. Diabetes Care 2011; 34: 491–496.
13. Sobngwi E, et al. Exposure over the life course to an urban environment and its relation with obesity, diabetes, and hypertension in rural and urban Cameroon. International Journal of Epidemiology 2004; 33: 769–776.
14. Hawkes C. Uneven dietary development: linking the policies and processes of globalization with the nutrition transition, obesity and diet-related chronic diseases. Globalization and Health 2006; 2: 4.
15. Kavishe B, et al. High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda. BMC Medicine 2015; 13: 126.
16. Ng M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766–781.
17. Torloni MR, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis. Obesity Reviews 2009; 10: 194–203.
18. Yu CK, Teoh TG, Robinson S. Obesity in pregnancy. British Journal of Obstetrics and Gynaecology 2006; 113: 1117–1125.
19. Yoge V, Visser GHA. Obesity, gestational diabetes and pregnancy outcome. Seminars in Fetal and Neonatal Medicine 2009; 14: 77–84.
20. Wendland EM, et al. Gestational diabetes and pregnancy outcomes – a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy and Childbirth 2012; 12: 23.
21. Ben-Haroush A, Yoge V, Hod M. Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabetic Medicine 2004; 21: 103–113.
22. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002; 25: 1862–1868.
23. Kaul P, et al. Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. Diabetic Medicine 2014; 32: 164–173.
24. Boney CM, et al. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 2005; 115: e290–e296.
25. Uauy R, Kain J, Corvalan C. How can the Developmental Origins of Health and Disease (DOHaD) hypothesis contribute to improving health in developing countries? *American Journal of Clinical Nutrition* 2011; 94(6 Suppl.): 1759s–1764s.

26. Barker DJ. Fetal origins of coronary heart disease. *BMJ (Clinical research ed)* 1995; 311: 171–174.

27. Barker DJ, et al. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993; 341: 938–941.

28. Gluckman PD, Hanson MA, Beedle AS. Non-genomic transgenerational inheritance of disease risk. *BioEssays* 2007; 29: 145–154.

29. Barker DJ. The origins of the developmental origins theory. *Journal of Internal Medicine* 2007; 261: 412–417.

30. Barker DJ, Bagby SP, Hanson MA. Mechanisms of disease: in utero programming in the pathogenesis of hypertension. *Nature Clinical Practice Nephrology* 2006; 2: 700–707.

31. UNAIDS. How AIDS Changed Everything Report – 2015. Geneva: UNAIDS, 2015.

32. Pawlowski A, et al. Tuberculosis and HIV Co-Infection. *Plos Pathogens* 2012; 8: e1002464.

33. WHO. Tuberculosis; fact sheet No. 104 2015. (http://www.who.int/mediacentre/factsheets/fs104/en/).

34. UNAIDS. Access to Antiretroviral Therapy in Africa; Status Report on Progress Towards the 2015 Targets. Geneva: UNAIDS, 2013.

35. WHO. Antimicrobial Resistance; Global Report on Surveillance. Geneva: World Health Organisation, 2014.

36. Okeke IN, et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. *Lancet Infectious Diseases* 2005; 5: 481–493.

37. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 2006; 444: 860–867.

38. Cruzz SM, Balkwill FR. Inflammation and cancer: advances and new agents. *Nature Reviews Clinical Oncology* 2015; 12: 584–596.

39. Young F, et al. A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and Diabetes Mellitus, HIV and Metabolic Syndrome, and the impact of globalization. *Globalization and Health* 2009; 5: 9.

40. Dillon DG, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. *International Journal of Epidemiology* 2013; 42: 1754–1771.

41. Brown TT, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. *Archives of Internal Medicine* 2005; 165: 1179–1184.

42. De Wit S, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008; 31: 1224–1229.

43. Triant VA, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *Journal of Clinical Endocrinology and Metabolism* 2007; 92: 2506–2512.

44. Shintani Y, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004; 126: 840–848.

45. Marzouk D, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. *Gut* 2007; 56: 1105–1110.

46. Wang CS, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. *American Journal of Epidemiology* 2007; 166: 196–203.

47. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. *International Journal of Medical Sciences* 2006; 3: 47–52.

48. Wang C, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. *International Journal of Cancer* 2012; 130: 1639–1648.

49. Genovese G, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science* 2010; 329: 841–845.

50. Gaziano TA, et al. Comparative assessment of absolute cardiovascular disease risk characterization from non-laboratory-based risk assessment in South African populations. *BMC Medicine* 2013; 11: 170.

51. Motala AA, et al. The prevalence of metabolic syndrome and determination of the optimal waist circumference cut-off points in a rural South African community. *Diabetes Care* 2011; 34: 1032–1037.

52. Crowther NJ, Norris SA. The current waist circumference cut point used for the diagnosis of metabolic syndrome in Sub-Saharan African women is not appropriate. *PLoS ONE* 2012; 7: e48883.

53. Mensah GA. Descriptive epidemiology of cardiovascular risk factors and diabetes in sub-Saharan Africa. *Progress in Cardiovascular Diseases* 2013; 56: 240–250.

54. Bonita R. Guest editorial: strengthening NCD prevention through risk factor surveillance. *Global Health Action* 2009; 2: 4–6.

55. Murphy GA, et al. Cardiometabolic risk in a rural Ugandan population. *Diabetes Care* 2013; 36: e143.

56. Kahn K, et al. Validation and application of verbal autopsies in a rural area of South Africa. *Tropical Medicine & International Health: TM & IH* 2000; 5: 824–831.

57. INDEPTH Network. 2015. (http://www.indepth-network.org/).

58. Asiki G, et al. The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies. *International Journal of Epidemiology* 2013; 42: 129–141.

59. Ng N, et al. Combining risk factors and demographic surveillance: potentials of WHO STEPS and INDEPTH methodologies for assessing epidemiological transition. *Scandinavian Journal of Public Health* 2006; 34: 199–208.

60. WHO. WHO STEPS Instrument (Core and Expanded): The WHO STEPwise Approach to Noncommunicable Disease Risk Factor Surveillance (STEPS). Geneva: World Health Organization, 2016.

61. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. *Lancet* 2006; 368: 1689–1695.

62. Maseko FC, Chirwa ML, Muula AS. Health systems challenges in cervical cancer prevention program in Malawi. *Global Health Action* 2015; 8: 26282.

63. Janssens B, et al. Offering integrated care for HIV/AIDS, diabetes and hypertension within chronic disease clinics in...
Cambodia. Bulletin of the World Health Organization 2007; 85: 880–885.

64. Atun R, et al. Improving responsiveness of health systems to non-communicable diseases. Lancet 2013; 381: 690–697.

65. van Olmen J, et al. Management of chronic diseases in Sub-Saharan Africa: cross-fertilisation between HIV/AIDS and diabetes care. Journal of Tropical Medicine 2012; 2012: 349312.

66. WHO. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. Geneva: World Health Organization, 2010.

67. Beaglehole R, et al. Improving the prevention and management of chronic disease in low-income and middle-income countries: a priority for primary health care. Lancet 2008; 372: 940–949.

68. Maher D, et al. Research needs for an improved primary care response to chronic non-communicable diseases in Africa. Tropical Medicine & International Health: TM & IH 2010; 15: 176–181.

69. Mahomed OH, Asmall S. Development and implementation of an integrated chronic disease model in South Africa: lessons in the management of change through improving the quality of clinical practice. International Journal of Integrated Care 2015; 15: e038.

70. de-Graft Aikins A, Boynton P, Atanga LL. Developing effective chronic disease interventions in Africa: insights from Ghana and Cameroon. Globalization and Health 2010; 6: 6.

71. Aminkeng F, et al. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics Journal 2014; 14: 160–170.

72. Ramos E, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics Journal 2014; 14: 217–222.

73. Drain PK, et al. Diagnostic point-of-care tests in resource-limited settings. Lancet Infectious Diseases 2014; 14: 239–249.

74. Pai NP, et al. Barriers to implementation of rapid and point-of-care tests for human immunodeficiency virus infection: findings from a systematic review (1996–2014). Point of Care 2015; 14: 81–87.

75. Horton R. Offline: chronic diseases – the social justice issue of our time. Lancet 2016; 386: 2378.

76. Collins R. What makes UK Biobank special? Lancet 2012; 379: 1173–1174.